Adjuvant Management of Pathologic Node–Positive Disease After Definitive Surgery for Clinical T1-2 N0 Rectal Cancer

Praveen Polamraju, Waqar Haque, Vivek Verma, Lee Wiederhold, Sandra Hatch, E. Brian Butler, Bin S. Teh

Research output: Contribution to journalArticle

Abstract

Introduction: Patients with cT1-2N0M0 rectal cancer are often treated with up-front surgical resection, with adjuvant treatment reserved for patients upstaged with pathologic node-positive (pN+) disease at surgery. This study evaluates practice patterns and clinical outcomes when comparing different forms of adjuvant treatment for this patient population. Methods: The National Cancer Data Base was queried for cT1-2N0M0 rectal cancer patients between 2004 and 2015 with postoperative pN+ disease treated without neoadjuvant treatment. Patients were divided into groups receiving observation, chemotherapy, or chemoradiotherapy (CRT). Multivariable logistic regression determined factors associated with receipt of adjuvant treatment. Kaplan-Meier curves compared overall survival (OS), and Cox regression determined patient factors associated with OS. Results: Altogether, 1466 patients met the inclusion criteria; 536 patients (36.6%) received adjuvant chemotherapy, 413 (28.2%) received adjuvant CRT, and 517 (35.3%) were observed postoperatively. Use of adjuvant treatment was associated with superior median OS (124.1 vs. 51.1 months, P <.001), persisting after propensity score matching (124.0 vs. 61.9 months, P <.001), but not between adjuvant CRT versus chemotherapy on subset analysis. Patients with positive surgical margins receiving adjuvant CRT showed a trend toward OS improvement compared to patients managed with chemotherapy (54.9 vs. 47.4 months, P =.10). Increased age, pN2 status, positive margin status, and observation were associated with poorer OS. Conclusion: Most patients found to have pN+ disease after up-front surgery for cT1-2N0 rectal cancer receive adjuvant treatment, which is associated with improved OS. Chemotherapy or CRT are appropriate options, although there was a trend toward higher OS for patients with positive surgical margins receiving CRT. Most patients with cT1-2N0M0 rectal cancer are treated surgically, followed by adjuvant treatment if pathologically positive lymph nodes are subsequently discovered. With the National Cancer Data Base, clinical outcomes for 1466 patients were compared on the basis of the type of adjuvant management received. Postoperative adjuvant treatment is associated with improved overall survival compared to observation and may be offered to patients.

LanguageEnglish (US)
JournalClinical Colorectal Cancer
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Rectal Neoplasms
Survival
Adjuvant Chemoradiotherapy
Chemoradiotherapy
Drug Therapy
Observation
Therapeutics
Physicians' Practice Patterns
Databases
Propensity Score
Neoadjuvant Therapy
Adjuvant Chemotherapy
Neoplasms

Keywords

  • Chemotherapy
  • Margins
  • Observation
  • Occult nodes
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Adjuvant Management of Pathologic Node–Positive Disease After Definitive Surgery for Clinical T1-2 N0 Rectal Cancer. / Polamraju, Praveen; Haque, Waqar; Verma, Vivek; Wiederhold, Lee; Hatch, Sandra; Butler, E. Brian; Teh, Bin S.

In: Clinical Colorectal Cancer, 01.01.2018.

Research output: Contribution to journalArticle

@article{a02b00351ca14efe9645858ed79dccc1,
title = "Adjuvant Management of Pathologic Node–Positive Disease After Definitive Surgery for Clinical T1-2 N0 Rectal Cancer",
abstract = "Introduction: Patients with cT1-2N0M0 rectal cancer are often treated with up-front surgical resection, with adjuvant treatment reserved for patients upstaged with pathologic node-positive (pN+) disease at surgery. This study evaluates practice patterns and clinical outcomes when comparing different forms of adjuvant treatment for this patient population. Methods: The National Cancer Data Base was queried for cT1-2N0M0 rectal cancer patients between 2004 and 2015 with postoperative pN+ disease treated without neoadjuvant treatment. Patients were divided into groups receiving observation, chemotherapy, or chemoradiotherapy (CRT). Multivariable logistic regression determined factors associated with receipt of adjuvant treatment. Kaplan-Meier curves compared overall survival (OS), and Cox regression determined patient factors associated with OS. Results: Altogether, 1466 patients met the inclusion criteria; 536 patients (36.6{\%}) received adjuvant chemotherapy, 413 (28.2{\%}) received adjuvant CRT, and 517 (35.3{\%}) were observed postoperatively. Use of adjuvant treatment was associated with superior median OS (124.1 vs. 51.1 months, P <.001), persisting after propensity score matching (124.0 vs. 61.9 months, P <.001), but not between adjuvant CRT versus chemotherapy on subset analysis. Patients with positive surgical margins receiving adjuvant CRT showed a trend toward OS improvement compared to patients managed with chemotherapy (54.9 vs. 47.4 months, P =.10). Increased age, pN2 status, positive margin status, and observation were associated with poorer OS. Conclusion: Most patients found to have pN+ disease after up-front surgery for cT1-2N0 rectal cancer receive adjuvant treatment, which is associated with improved OS. Chemotherapy or CRT are appropriate options, although there was a trend toward higher OS for patients with positive surgical margins receiving CRT. Most patients with cT1-2N0M0 rectal cancer are treated surgically, followed by adjuvant treatment if pathologically positive lymph nodes are subsequently discovered. With the National Cancer Data Base, clinical outcomes for 1466 patients were compared on the basis of the type of adjuvant management received. Postoperative adjuvant treatment is associated with improved overall survival compared to observation and may be offered to patients.",
keywords = "Chemotherapy, Margins, Observation, Occult nodes, Radiotherapy",
author = "Praveen Polamraju and Waqar Haque and Vivek Verma and Lee Wiederhold and Sandra Hatch and Butler, {E. Brian} and Teh, {Bin S.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.clcc.2018.04.001",
language = "English (US)",
journal = "Clinical Colorectal Cancer",
issn = "1533-0028",
publisher = "Elsevier",

}

TY - JOUR

T1 - Adjuvant Management of Pathologic Node–Positive Disease After Definitive Surgery for Clinical T1-2 N0 Rectal Cancer

AU - Polamraju, Praveen

AU - Haque, Waqar

AU - Verma, Vivek

AU - Wiederhold, Lee

AU - Hatch, Sandra

AU - Butler, E. Brian

AU - Teh, Bin S.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Introduction: Patients with cT1-2N0M0 rectal cancer are often treated with up-front surgical resection, with adjuvant treatment reserved for patients upstaged with pathologic node-positive (pN+) disease at surgery. This study evaluates practice patterns and clinical outcomes when comparing different forms of adjuvant treatment for this patient population. Methods: The National Cancer Data Base was queried for cT1-2N0M0 rectal cancer patients between 2004 and 2015 with postoperative pN+ disease treated without neoadjuvant treatment. Patients were divided into groups receiving observation, chemotherapy, or chemoradiotherapy (CRT). Multivariable logistic regression determined factors associated with receipt of adjuvant treatment. Kaplan-Meier curves compared overall survival (OS), and Cox regression determined patient factors associated with OS. Results: Altogether, 1466 patients met the inclusion criteria; 536 patients (36.6%) received adjuvant chemotherapy, 413 (28.2%) received adjuvant CRT, and 517 (35.3%) were observed postoperatively. Use of adjuvant treatment was associated with superior median OS (124.1 vs. 51.1 months, P <.001), persisting after propensity score matching (124.0 vs. 61.9 months, P <.001), but not between adjuvant CRT versus chemotherapy on subset analysis. Patients with positive surgical margins receiving adjuvant CRT showed a trend toward OS improvement compared to patients managed with chemotherapy (54.9 vs. 47.4 months, P =.10). Increased age, pN2 status, positive margin status, and observation were associated with poorer OS. Conclusion: Most patients found to have pN+ disease after up-front surgery for cT1-2N0 rectal cancer receive adjuvant treatment, which is associated with improved OS. Chemotherapy or CRT are appropriate options, although there was a trend toward higher OS for patients with positive surgical margins receiving CRT. Most patients with cT1-2N0M0 rectal cancer are treated surgically, followed by adjuvant treatment if pathologically positive lymph nodes are subsequently discovered. With the National Cancer Data Base, clinical outcomes for 1466 patients were compared on the basis of the type of adjuvant management received. Postoperative adjuvant treatment is associated with improved overall survival compared to observation and may be offered to patients.

AB - Introduction: Patients with cT1-2N0M0 rectal cancer are often treated with up-front surgical resection, with adjuvant treatment reserved for patients upstaged with pathologic node-positive (pN+) disease at surgery. This study evaluates practice patterns and clinical outcomes when comparing different forms of adjuvant treatment for this patient population. Methods: The National Cancer Data Base was queried for cT1-2N0M0 rectal cancer patients between 2004 and 2015 with postoperative pN+ disease treated without neoadjuvant treatment. Patients were divided into groups receiving observation, chemotherapy, or chemoradiotherapy (CRT). Multivariable logistic regression determined factors associated with receipt of adjuvant treatment. Kaplan-Meier curves compared overall survival (OS), and Cox regression determined patient factors associated with OS. Results: Altogether, 1466 patients met the inclusion criteria; 536 patients (36.6%) received adjuvant chemotherapy, 413 (28.2%) received adjuvant CRT, and 517 (35.3%) were observed postoperatively. Use of adjuvant treatment was associated with superior median OS (124.1 vs. 51.1 months, P <.001), persisting after propensity score matching (124.0 vs. 61.9 months, P <.001), but not between adjuvant CRT versus chemotherapy on subset analysis. Patients with positive surgical margins receiving adjuvant CRT showed a trend toward OS improvement compared to patients managed with chemotherapy (54.9 vs. 47.4 months, P =.10). Increased age, pN2 status, positive margin status, and observation were associated with poorer OS. Conclusion: Most patients found to have pN+ disease after up-front surgery for cT1-2N0 rectal cancer receive adjuvant treatment, which is associated with improved OS. Chemotherapy or CRT are appropriate options, although there was a trend toward higher OS for patients with positive surgical margins receiving CRT. Most patients with cT1-2N0M0 rectal cancer are treated surgically, followed by adjuvant treatment if pathologically positive lymph nodes are subsequently discovered. With the National Cancer Data Base, clinical outcomes for 1466 patients were compared on the basis of the type of adjuvant management received. Postoperative adjuvant treatment is associated with improved overall survival compared to observation and may be offered to patients.

KW - Chemotherapy

KW - Margins

KW - Observation

KW - Occult nodes

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85046695420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046695420&partnerID=8YFLogxK

U2 - 10.1016/j.clcc.2018.04.001

DO - 10.1016/j.clcc.2018.04.001

M3 - Article

JO - Clinical Colorectal Cancer

T2 - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

SN - 1533-0028

ER -